The peripheral stents market size was valued at USD 5.75 billion in 2025 and estimated to grow from USD 6.17 billion in 2026 to reach USD 8.73 billion by 2031, at a CAGR of 7.24% during the forecast period (2026-2031). This report is Segmented by Product (Bare Metal Stents, Covered Stents, and More), Artery Type (Iliac Stents, Femoral-Popliteal Stents, and More), Material (Nitinol, Stainless Steel and More), Deployment of Mechanism (Balloon-Expandable and Self-Expanding), End User (Hospitals, Ambulatory Surgical Centers and More), and Geography. The Market Forecasts are Provided in Terms of Value (USD).
Physicians cite the Eluvia system’s one-year patency record and the Esprit BTK scaffold’s dissolving profile as evidence that new chemistry and coatings can outperform legacy metal frames. Growing clinical confidence, combined with reimbursement alignment for innovative therapies, fuels capital budgets aimed at next-generation products. As data matures, the peripheral stents market is likely to rebalance toward platforms that combine proven drug delivery with resorption to minimize long-term complications.
Femoral-popliteal interventions generated 35.88% of 2025 revenue, underscoring their central role in PAD management. That dominance rests on a large installed base of equipment and clinical protocols perfected over decades. Yet infrapopliteal procedures are tipped for 9.32% CAGR, eclipsing all other artery categories. The introduction of purpose-built below-the-knee scaffolds, improved imaging, and rising chronic limb-threatening ischemia awareness underpin that growth. Iliac, renal, and carotid segments maintain steady demand, but incremental gains remain modest relative to infrapopliteal momentum.
Infrapopliteal devices benefit from unmet clinical need, as earlier interventions extend limb salvage and improve quality of life. Successful early outcomes from dissolving platforms are expected to widen physician adoption. That shift will expand the peripheral stents market share devoted to distal limb revascularization, especially as clinical guidelines endorse earlier BTK treatment.
Europe follows closely, propelled by harmonized clinical guidelines and a single-market regulatory environment that speeds cross-border adoption. The European Society for Vascular Surgery emphasizes individualized care and endorses drug-eluting systems, supporting the peripheral stents market across member states. Western European countries benefit from established value-based care frameworks, and Central & Eastern Europe show emerging growth as infrastructure modernizes.
Asia-Pacific is the fastest climber, advancing at a 8.90% CAGR through 2031. China’s target-lesion failure dropped from 6.8% to 4.3% between 2023 and 2024 as advanced stents penetrated tier-one cities. India, aided by updated Medical Device Rules, recorded peripheral interventions rising from 2,850 in 2023 to 3,420 in 2024. South Korea and Japan remain technology-forward, quickly incorporating AI imaging and next-generation materials. Improved payor coverage and government focus on cardiovascular disease drive capacity expansion, lifting the peripheral stents market.
Latin America and the Middle East & Africa present untapped opportunity. Reimbursement variability and budget constraints slow uptake, but epidemiological transition and public-health campaigns create long-term upside. Pilot projects with cost-sharing models may establish proof-points that unlock broader adoption. As training partnerships and mobile cath-labs proliferate, regional stakeholders anticipate gradual but steady contribution to global volumes.
Global Peripheral Stent Market Trends and Insights
Growing Burden of PAD and Aging Population
PAD procedure volumes climbed from 933 in 2023 to 1,422 in 2024 across major systems, underscoring a widening patient pool. Prevalence touches 20% among people over 70, creating a durable base for intervention. Smoking and hypertension remain core risk factors, together accounting for nearly 70% of disease burden. Developed regions show the highest prevalence, but emerging markets such as South Korea recorded incidence growth from 2.68 to 3.09 per 1,000 persons between 2023 and 2024 as diagnostic reach improves. These demographic realities assure sustained demand for interventions and keep the peripheral stents market moving upward.Rapid Adoption of Drug-Eluting & Bio-Resorbable Platforms
Drug-eluting devices already hold majority share, while bio-resorbable scaffolds log double-digit growth as new evidence accumulates. FDA clearance of Abbott’s Esprit BTK system in 2024 delivered the first below-the-knee dissolving stent in the United States and reduced restenosis 25.8% versus balloon angioplasty. Registry data for magnesium scaffolds showed 4.3% target lesion failure at 12 months, fuelling clinical confidence. The shift supports the broader “leave nothing behind” strategy, pushing the peripheral stents market toward next-generation solutions.Lengthy Regulatory Pathways for Novel Materials
The FDA’s Quality Management System Regulation overhaul effective February 2026 adds process layers for magnesium and polymer platforms, prolonging time-to-market. De Novo submissions face demanding evidence rules that favor incumbents familiar with compliance. These hurdles can slow innovation diffusion and dampen growth in the peripheral stents market FDA.Other drivers and restraints analyzed in the detailed report include:
- Shift to Minimally-Invasive Day-Care Procedures
- AI-Guided Image-Based Sizing & Placement Optimisation
- Price Erosion From Group Purchasing Organisations
Segment Analysis
Drug-eluting stents retained 51.66% of 2025 revenue and are forecast to advance steadily as clinical familiarity persists. The peripheral stents market size for drug-eluting platforms is projected to rise in line with the overall 7.24% CAGR, supported by ongoing design refinements that boost patency. Bio-resorbable scaffolds, while only a fraction of sales today, are tracking 10.05% CAGR, the fastest within the product mix, thanks to FDA endorsements that validate safety and efficacy. Covered and bare-metal devices meet niche needs but face share migration toward higher-performing alternatives.Physicians cite the Eluvia system’s one-year patency record and the Esprit BTK scaffold’s dissolving profile as evidence that new chemistry and coatings can outperform legacy metal frames. Growing clinical confidence, combined with reimbursement alignment for innovative therapies, fuels capital budgets aimed at next-generation products. As data matures, the peripheral stents market is likely to rebalance toward platforms that combine proven drug delivery with resorption to minimize long-term complications.
Femoral-popliteal interventions generated 35.88% of 2025 revenue, underscoring their central role in PAD management. That dominance rests on a large installed base of equipment and clinical protocols perfected over decades. Yet infrapopliteal procedures are tipped for 9.32% CAGR, eclipsing all other artery categories. The introduction of purpose-built below-the-knee scaffolds, improved imaging, and rising chronic limb-threatening ischemia awareness underpin that growth. Iliac, renal, and carotid segments maintain steady demand, but incremental gains remain modest relative to infrapopliteal momentum.
Infrapopliteal devices benefit from unmet clinical need, as earlier interventions extend limb salvage and improve quality of life. Successful early outcomes from dissolving platforms are expected to widen physician adoption. That shift will expand the peripheral stents market share devoted to distal limb revascularization, especially as clinical guidelines endorse earlier BTK treatment.
Complete Report Scope:
- By Product
- Bare-Metal Stents (BMS)
- Covered Stents
- Drug-Eluting Stents (DES)
- Bio-resorbable Vascular Scaffolds (BVS)
- By Artery Type
- Iliac Artery Stents
- Femoral-Popliteal Stents
- Renal & Related Artery Stents
- Carotid Artery Stents
- Infrapopliteal (Below-knee) Stents
- By Material
- Nitinol
- Cobalt-Chromium
- Stainless Steel
- Polymer / Composite
- By Deployment Mechanism
- Balloon-Expandable
- Self-Expanding
- By End User
- Hospitals
- Ambulatory Surgical Centers (ASCs)
- Others
- By Geography
- North America
- United States
- Canada
- Mexico
- Europe
- Germany
- United Kingdom
- France
- Italy
- Spain
- Rest of Europe
- Asia-Pacific
- China
- Japan
- India
- Australia
- South Korea
- Rest of Asia-Pacific
- Middle East and Africa
- GCC
- South Africa
- Rest of Middle East and Africa
- South America
- Brazil
- Argentina
- Rest of South America
- North America
Geography Analysis
North America generated 38.55% of 2025 revenue, with the United States representing the largest single market due to well-funded health systems, routine screening, and broad reimbursement for endovascular care. Canada and Mexico contribute incrementally as access widens, though reimbursement and regulatory nuances shape product mix. Successful large-scale adoption of drug-eluting and bio-resorbable solutions solidifies regional leadership.Europe follows closely, propelled by harmonized clinical guidelines and a single-market regulatory environment that speeds cross-border adoption. The European Society for Vascular Surgery emphasizes individualized care and endorses drug-eluting systems, supporting the peripheral stents market across member states. Western European countries benefit from established value-based care frameworks, and Central & Eastern Europe show emerging growth as infrastructure modernizes.
Asia-Pacific is the fastest climber, advancing at a 8.90% CAGR through 2031. China’s target-lesion failure dropped from 6.8% to 4.3% between 2023 and 2024 as advanced stents penetrated tier-one cities. India, aided by updated Medical Device Rules, recorded peripheral interventions rising from 2,850 in 2023 to 3,420 in 2024. South Korea and Japan remain technology-forward, quickly incorporating AI imaging and next-generation materials. Improved payor coverage and government focus on cardiovascular disease drive capacity expansion, lifting the peripheral stents market.
Latin America and the Middle East & Africa present untapped opportunity. Reimbursement variability and budget constraints slow uptake, but epidemiological transition and public-health campaigns create long-term upside. Pilot projects with cost-sharing models may establish proof-points that unlock broader adoption. As training partnerships and mobile cath-labs proliferate, regional stakeholders anticipate gradual but steady contribution to global volumes.
List of Companies Covered in this Report:
- Abbott Laboratories
- Beckton Dickinson
- Boston Scientific
- Medtronic
- Terumo
- Cook Group
- Lifetech Scientific
- MicroPort
- Stryker
- Gore Medical
- Cordis
- Endologix LLC
- B. Braun
- Getinge
- iVascular S.L.U.
- Elixir Medical
- Alvimedica
Additional Benefits:
- The market estimate (ME) sheet in Excel format
- 3 months of analyst support
Table of Contents
1 Introduction
4 Market Landscape
5 Market Size and Growth Forecasts (Value-USD)
6 Competitive Landscape
7 Market Opportunities and Future Outlook
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Abbott Laboratories
- Becton Dickinson
- Boston Scientific Corporation
- Medtronic plc
- Terumo Corporation
- Cook Medical
- Lifetech Scientific
- MicroPort Scientific
- Stryker
- Gore Medical
- Cordis
- Endologix LLC
- B. Braun Melsungen AG
- Getinge
- iVascular S.L.U.
- Elixir Medical
- Alvimedica
